Daniel Slotta
Research expert covering finance, real estate, and technology in Greater China
Get in touch with us nowIn 2023, the domestic initial public offering value of Chinese companies from the biotechnology and pharmaceutical industry amounted to over 31 billion yuan. Chinese companies went public despite the outbreak of COVID-19 and the resulting turbulences at various financial markets around the world. The Chinese government tries to develop the domestic financial market to incentivize Chinese companies to list at home.
You only have access to basic statistics.
This statistic is not included in your account.
Business Solutions including all features.
Overview
IPOs in Mainland China
IPOs in Hong Kong
Chinese IPOs overseas
Special focus: SPACs
Special focus: U.S. listed Chinese companies
Further related statistics